MX2017010930A - Compuesto de piridina biciclica. - Google Patents
Compuesto de piridina biciclica.Info
- Publication number
- MX2017010930A MX2017010930A MX2017010930A MX2017010930A MX2017010930A MX 2017010930 A MX2017010930 A MX 2017010930A MX 2017010930 A MX2017010930 A MX 2017010930A MX 2017010930 A MX2017010930 A MX 2017010930A MX 2017010930 A MX2017010930 A MX 2017010930A
- Authority
- MX
- Mexico
- Prior art keywords
- lap
- compound
- inhibition
- nocturia
- antidiuretic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El problema a resolver mediante la presente invención es proveer un compuesto adecuado para una composición farmacéutica, en especial una composición farmacéutica para tratar la nocturia. Los inventores han asumido que la inhibición de la actividad nocturna de la leucina aminopeptidasa placentaria (P-LAP), o sea aminopeptidasa que escinde AVP, mantendría y/o incrementaría un nivel endógeno de AVP para aumentar el efecto antidiurético, lo que contribuiría a un menor número de vaciamientos nocturnos, y han estudiado exhaustivamente los compuestos que inhiben a P-LAP. Como resultado, los inventores han hallado que los derivados del ácido (2R)-3-amino-2-(bi-cíclicopiridilmetil)-2-hidroxi-propanoico tienen una excelente actividad inhibitoria de P-LAP. Los inventores han evaluado efectos antidiuréticos en ratas administradas con agua y han hallado que los compuestos incrementan los niveles endógenos de AVP mediante la inhibición de P-LAP, y como consecuencia reducen la producción de orina. La presente invención por lo tanto provee compuestos que se espera que se usen como agentes para tratar la nocturia en base a la inhibición de P-LAP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015046121 | 2015-03-09 | ||
| PCT/JP2015/083345 WO2016143200A1 (ja) | 2015-03-09 | 2015-11-27 | 二環式ピリジン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010930A true MX2017010930A (es) | 2018-01-23 |
| MX370920B MX370920B (es) | 2020-01-09 |
Family
ID=56880128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010930A MX370920B (es) | 2015-03-09 | 2015-11-27 | Compuesto de piridina bicíclica. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10023583B2 (es) |
| EP (1) | EP3269721B1 (es) |
| JP (1) | JP6646648B2 (es) |
| KR (1) | KR102446212B1 (es) |
| CN (1) | CN107428768B (es) |
| AR (1) | AR102849A1 (es) |
| AU (1) | AU2015386039B2 (es) |
| BR (1) | BR112017018649B8 (es) |
| CA (1) | CA2976746C (es) |
| CO (1) | CO2017008372A2 (es) |
| ES (1) | ES2869924T3 (es) |
| IL (1) | IL254307B (es) |
| MX (1) | MX370920B (es) |
| MY (1) | MY198083A (es) |
| PH (1) | PH12017501596A1 (es) |
| PL (1) | PL3269721T3 (es) |
| PT (1) | PT3269721T (es) |
| RU (1) | RU2700411C2 (es) |
| SG (1) | SG11201706745PA (es) |
| TW (1) | TWI700285B (es) |
| UA (1) | UA121889C2 (es) |
| WO (1) | WO2016143200A1 (es) |
| ZA (1) | ZA201706038B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868215A4 (en) | 2018-10-16 | 2022-07-27 | Nippon Chemiphar Co., Ltd. | MEANS OF IMPROVING SLEEP QUALITY |
| EP3868370A4 (en) | 2018-10-17 | 2022-06-29 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for nocturia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ553688A (en) | 2004-09-09 | 2011-05-27 | Florey Howard Inst | Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase |
| BRPI0712680A2 (pt) * | 2006-06-08 | 2012-11-20 | Lilly Co Eli | antagonistas de receptor de mch |
| NZ585338A (en) | 2007-11-19 | 2012-08-31 | Howard Florey Inst | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| TW201031652A (en) | 2008-11-06 | 2010-09-01 | Astellas Pharma Inc | Carbamic acid ester compound or salt thereof |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| DK2615089T3 (en) * | 2010-09-07 | 2016-06-06 | Astellas Pharma Inc | Pyrazoloquinolinforbindelser |
| JP2015528801A (ja) * | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| MX2016015549A (es) | 2014-05-28 | 2017-03-23 | Astellas Pharma Inc | Derivado de piridina. |
-
2015
- 2015-11-26 AR ARP150103899A patent/AR102849A1/es unknown
- 2015-11-27 KR KR1020177020910A patent/KR102446212B1/ko active IP Right Grant
- 2015-11-27 CA CA2976746A patent/CA2976746C/en active Active
- 2015-11-27 MY MYPI2017703298A patent/MY198083A/en unknown
- 2015-11-27 CN CN201580077585.XA patent/CN107428768B/zh active Active
- 2015-11-27 US US15/551,222 patent/US10023583B2/en active Active
- 2015-11-27 WO PCT/JP2015/083345 patent/WO2016143200A1/ja active Application Filing
- 2015-11-27 ES ES15884684T patent/ES2869924T3/es active Active
- 2015-11-27 RU RU2017134316A patent/RU2700411C2/ru active
- 2015-11-27 BR BR112017018649A patent/BR112017018649B8/pt active IP Right Grant
- 2015-11-27 PL PL15884684T patent/PL3269721T3/pl unknown
- 2015-11-27 TW TW104139686A patent/TWI700285B/zh active
- 2015-11-27 UA UAA201709737A patent/UA121889C2/uk unknown
- 2015-11-27 AU AU2015386039A patent/AU2015386039B2/en active Active
- 2015-11-27 MX MX2017010930A patent/MX370920B/es active IP Right Grant
- 2015-11-27 EP EP15884684.0A patent/EP3269721B1/en active Active
- 2015-11-27 SG SG11201706745PA patent/SG11201706745PA/en unknown
- 2015-11-27 PT PT158846840T patent/PT3269721T/pt unknown
- 2015-11-27 JP JP2017504564A patent/JP6646648B2/ja active Active
-
2017
- 2017-08-16 CO CONC2017/0008372A patent/CO2017008372A2/es unknown
- 2017-09-04 IL IL254307A patent/IL254307B/en active IP Right Grant
- 2017-09-05 ZA ZA2017/06038A patent/ZA201706038B/en unknown
- 2017-09-05 PH PH12017501596A patent/PH12017501596A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501877A1 (en) | Substituted indole mcl-1 inhibitors | |
| EA201792047A1 (ru) | Новые соединения | |
| MX2019007234A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos. | |
| PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| CR20200441A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2022010638A (es) | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. | |
| MX2012002066A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2020006414A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| MX2015014944A (es) | Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer. | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| MX2023000191A (es) | Metodos de fabricacion y uso de inhibidores de pde9. | |
| MX2014007969A (es) | Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8. | |
| MX371152B (es) | Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk). | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| MX2019014665A (es) | Nuevos derivados de azaindolina sustituida como inhibidores de nik. | |
| MX2019002259A (es) | Inhibicion de la actividad de la olig2. | |
| PH12017501596A1 (en) | Bicyclic pyridine compound | |
| EA201590884A1 (ru) | Способы лечения заболеваний печени | |
| PH12016502344A1 (en) | Pyridine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |